Nutritional Therapy in Patients With Post-extubation Dysphagia

November 9, 2026 updated by: Ivan Armando Osuna Padilla, National Institute of Respiratory Diseases, Mexico

Swallowing and Nutritional Therapy and Its Impact on Body Composition and Clinical Outcomes in Patients With Post-extubation Dysphagia

The aim of this study is to evaluate the impact of the prescription of two doses of protein on the amount in kilograms of muscle mass and on the clinical evolution (time until safe swallowing, time until removal of the feeding stoma, number of hospital readmissions, feeding stoma infections, incidence of pneumonia, functionality, number of falls, fractures and mortality) at 6 months after hospital discharge in patients with enteral nutrition due to post-extubation dysphagia.

Study Overview

Status

Suspended

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

128

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Mexico City, Mexico, 14080
        • National Institute of Respiratory Diseases

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients who required invasive mechanical ventilation during their hospital stay with a diagnosis of post-extubation dysphagia diagnosed by fibroendoscopy evaluation of swallowing (FEES).
  • Patients who discharged with a feeding tube.
  • Patients with signed informed consent.

Exclusion Criteria:

  • Patients with pre-existing dysphagia, or with neurological conditions that can cause dysphagia (e.g. multiple sclerosis, Parkinson's disease, Alzheimer's, myasthenia gravis).
  • Patients with chronic kidney disease, defined as a glomerular filtration rate <60 ml/min.
  • Patients discharged with a terminal condition and/or life expectancy of less than 3 months.
  • Diagnosis of HIV, upon receiving clinical follow-up by the team of specialists.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High protein group

100% of the energy requirements measured by indirect calorimetry (IC) or estimated, and a protein intake of 2.0 g/kg, will be prescribed

High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition

Other: Usual protein group

100% of the energy requirements measured by IC or estimated, and a protein intake of 1.5 g/kg, will be prescribed.

Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle mass changes
Time Frame: From randomization to 6 months

Changes of muscle mass in kilograms measured by impedance bioelectric

From randomization to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Swallow recovery
Time Frame: From randomization to 6 months

Time to safe swallowing diagnosed by fibroendoscopy evaluation of swallowing (FEES) and measured in months

From randomization to 6 months
Duration of enteral nutrition indication
Time Frame: From randomization to 6 months

Time from discharge to feeding tube removal

From randomization to 6 months
Feeding tube complications
Time Frame: From randomization to 6 months

Number of feeding tube infections, dysfunctions and oclusions during study period

From randomization to 6 months
Muscle functionality changes
Time Frame: From randomization to 6 months

Changes in functionality measured by medical research council scale in a scale of 0-60 points

From randomization to 6 months
Handgrip strenght changes
Time Frame: From randomization to 6 months

Changes in functionality assessed by handgrip strenght in kilogramos using a digital dynamometer

From randomization to 6 months
Frailty complications
Time Frame: From randomization to 6 months

Number of falls and fractures during study period

From randomization to 6 months
Hospital readmissions associated to dysphagia complications
Time Frame: From randomization to 6 months

Number of hospital readmissions assocciated to feeding tube infections, dysfunctions and oclusions during study period

From randomization to 6 months
6-month mortality
Time Frame: From randomization to 6 months

All-cause mortality during study period

From randomization to 6 months
Aspiration pneumonia incidence
Time Frame: From randomization to 6 months

Number of hospital readmissions due to aspiration pneumonia

From randomization to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Ivan A Osuna-Padilla, PhD, Instituto Nacional de Enfermedades Respiratorias

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2024

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

July 10, 2024

First Submitted That Met QC Criteria

July 15, 2024

First Posted (Actual)

July 19, 2024

Study Record Updates

Last Update Posted (Actual)

November 13, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • C32-24

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.